Mr. Brendan Brennan has served as Chief Financial Officer since February 2012. Mr. Brennan has developed his career over the last 21 years from experience in various industries. Mr. Brennan joined ICON in 2006 and he has served in a number of senior finance roles in the Company including the role of Senior Vice President of Corporate Finance. Prior to this he developed his broad financial experience in Cement Roadstone Holdings, a major Irish building materials organization. Mr. Brennan spent a number of years in public accounting with PwC prior to this. Mr. Brennan is a Fellow of the Institute of Chartered Accountants in Ireland and holds a bachelor’s degree in Accounting and Finance from Dublin City University. Over his many years of experience in the CRO industry Mr. Brennan has been involved in many industry organizations and developments including ACRO (Association of Clinical Research Organizations) where he was the founding Chairman of the industry CFO round table group, a group formed to aid CROs dealing with the various industry challenges. Mr. Brennan held the position of Chairman of the round table from its foundation in 2017 to December 31, 2019.

Mr. Barry Balfe is President Global Operations (Large Pharma). Mr. Balfe previously served as President of ICON Functional Services (IFS). Mr. Balfe has been with ICON for over fifteen years and has held a number of senior roles, predominantly within the DOCS organisation, where he has successfully grown this business and has developed and led a number of new strategic partnerships. Mr. Balfe was previously EVP, Global Business Development. As part of the DOCS team, Mr. Balfe served as Senior Vice-President, Global Program Management where he oversaw operational design, planning & delivery within DOCS' resourcing & FSP businesses. He initially joined ICON’s Business Development team in 2003, before taking on the leadership of DOCS' US Business in early 2007 and subsequently overseeing DOCS' European Operations. Mr. Balfe holds a Bachelor of Science degree in chemistry, having studied at Dublin City University and Ecole Nationale Supérieure de Chimie de Toulouse. He subsequently studied pharmacoepidemiology and pharmacovigilance at London School of Hygiene and Tropical Medicine, the University of London.

Dr. Greg Licholai is Chief Medical and Information Officer at ICON plc, a global healthcare intelligence and clinical research organization. He is on the faculty at Yale School of Management and is Co-Director of the Center for Digital Health. Previously, he was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he ran the healthcare data service line. He was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates. He was co-founder of Immunome Therapeutics.

Greg has degrees from Harvard Business School, Yale School of Medicine, Columbia University and Boston College. He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. He serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). He writes about innovation in healthcare for Forbes.

Mr. Diarmaid Cunningham is Chief Administrative Officer, General Counsel, Executive Vice President and Company Secretary. 

Mr. Cunningham joined the Company as General Counsel in November 2009.  From 2009 until 2013, Mr. Cunningham was based in the Company’s global headquarters in Dublin.  In 2013, Mr. Cunningham was seconded to the Company’s US headquarters in Pennsylvania and that secondment ended in 2018 when Mr. Cunningham returned to Dublin.

In July 2016, Mr. Cunningham’s role expanded to include Chief Administrative Officer in addition to General Counsel. This expansion of his role means Mr. Cunningham has responsibility to the Company’s Quality Assurance, Client Contracts Services, Facilities and Procurement groups in addition to his responsibility for the Company’s Legal group.

Mr. Cunningham graduated with a Bachelor of Business and Legal Studies from University College Dublin in 1997, qualified as a lawyer in 2001 and completed the Stanford Executive Program at Stanford University in California in 2015.  Mr. Cunningham served as Secretary to the Board of the Association of Clinical Research Organizations (ACRO) in 2013 and 2014 and 2020 and has been appointed again for 2021. ACRO represents the CRO industry globally to key stakeholders including pharmaceutical, biotech and medical device companies, regulators, legislators and patient groups.

Prior to joining the Company, Mr. Cunningham spent 10 years with A&L Goodbody, one of Ireland's premier corporate law firms.

In January 2021, Mr. Cunningham was appointed as a non-executive director of the Irish charity The Jack & Jill Foundation.

Dr. Ute Berger is President, Development & Commercialisation Solutions covering a diverse range of services including; Decentralised Clinical Trial Solutions, Early Clinical & Bioanalytical Solutions, Laboratory Solutions, Site & Patient Solutions, Commercialisation & Outcomes, and Consulting Services.   She has 20+ years of clinical experience in academia and extensive experience in clinical research across all therapeutic areas, with a particular focus on malignant haematology and oncology. Prior to her current role Dr. Berger led the Medical & Scientific Affairs team globally across all therapeutic areas and also the pharmacovigilance and patient safety team.

Before joining ICON Dr. Berger held numerous professional positions including Medical Coordinator for the German Chronic Myelogenous Leukemia Study Centre as well as General Manager of the German Competence Network "Acute and Chronic Leukemia’s" where she has been instrumental in setting up a nationwide innovative research structure.  As the Scientific Network Manager of the "European LeukemiaNet" she deployed a similar collaborative research structure across Europe.  She was previously a Board Member of the Telematikplattform eV, a platform for medical research networks, which was set up to provide technical, legal and organisational solutions for data exchange in clinical research.

Dr. Berger is board certified in Internal Medicine, Haematology, and Medical Oncology and received her medical degree from the University of Heidelberg, Germany.  She is certified by the European Society of Medical Oncology, has published extensively in prominent journals and presented at numerous scientific conferences.